The National Cancer Institute (NCI) has made a strong commitment to supporting the development and application of novel and potentially paradigm-shifting technologies in the Nation's continuing battle against cancer. Since 1999, the Innovative Molecular Analysis Technologies (IMAT, http://innovation.cancer.gov) program has been a central part of this effort, supporting innovative and emerging technologies of interest for cancer research and cancer medicine. We are very pleased to invite you to participate in NCI's Thirteenth Principal Investigators (PI) Meeting for the IMAT program to be held on November 27-28, 2012 at the Methodist Hospital Research Institute in Houston, Texas.
The intent of the IMAT PI meeting is to provide the opportunity for participants in this program to share their ideas and progress in an open forum with investigators representing a broad range of scientific expertise. In addition, we would like to use this opportunity to share information with you on complementary NCI programs and NCI research resources as well as to solicit your ideas on how the NCI can accelerate your progress in developing new molecular analysis technologies for cancer research.
In accordance with guidelines in the grant, all PIs are expected to personally participate in the meeting utilizing the budgetary resources allocated for travel in their original IMAT applications. In the unfortunate event that previous commitments preclude your attendance, we would recommend the attendance of an appropriate senior member of your research team. We appreciate that for some projects critical direction is also being provided by a co-PI, and will consider requests for the attendance of this investigator as a second representative of the project at the meeting. These requests should be addressed to Susan Kerin, at email@example.com or (301) 468-6072. In general, we are limiting attendance to the PI on the award.